Puzi City

Researchers are evaluating the effectiveness and safety of pirtobrutinib LOXO-305 compared to ibrutinib in participants with chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. The study includes participants who may or may not have received prior treatment for their cancer. Part 1 of the trial lasts up to six years, while Part 2 focuses on treatment-nafve participants with a specific genetic deletion 17p deletion and lasts up to two years. Participants will receive pirtobrutinib or ibrutinib orally, depending on their assigned study group. Part 1 compares pirtobrutinib to ibrutinib in a randomized, open-label design. Part 2 evaluates pirtobrutinib alone in participants with the 17p deletion who have not yet been treated. Treatment continues until disease progression, unacceptable side effects, or other study-defined reasons. During the study, participants undergo regular assessments including clinical evaluations and monitoring of their response to treatment using established criteria. Researchers measure overall response rates, progression-free survival, event-free survival, duration of response, overall survival, time to next treatment, symptom worsening, and treatment tolerability. Participation involves ongoing monitoring for up to six years in Part 1 and two years in Part 2 to evaluate long-term outcomes and safety.

Researchers are evaluating the effects of starting a combination of moderate-intensity statin plus ezetimibe versus moderate- or high-intensity statin alone in patients who recently had an ischemic stroke or transient ischemic attack TIA and have atherosclerosis. This randomized controlled trial aims to determine which treatment better lowers LDL cholesterol levels to below 70 mgdL, with participants recruited within 30 days after their stroke or TIA. The study is conducted across six medical institutions in Taiwan and sponsored by Chang Gung Memorial Hospital. Participants will be randomly assigned to one of two groups the experimental group receiving a fixed-dose combination of statin and ezetimibe such as simvastatin 20mgezetimibe 10mg, atorvastatin 20mgezetimibe 10mg, rosuvastatin 10mgezetimibe 10mg, or ezetimibe added to moderate-intensity statins or the control group receiving moderate- or high-intensity statin monotherapy including atorvastatin 10-80 mgday, rosuvastatin 5-20 mgday, or pitavastatin 1-4 mgday. Treatment starts within 2 days after randomization. During the study, participants will have their LDL cholesterol levels measured at 3 and 6 months after randomization to assess treatment effects. Researchers will monitor LDL-C levels to see if they reach below 70 mgdL, the primary outcome measured at 6 months. Patients will be screened by research assistants and attending physicians for eligibility, and the trial runs until July 2029, involving adults aged 20 to 100 years old who had recent ischemic stroke or TIA with LDL-C levels of 100 mgdL or higher and evidence of atherosclerosis.

Researchers are evaluating the real-world effectiveness and safety of Nebilet4 nebivolol in adults with hypertension across seven Asian countries. This multinational, multicenter, observational, and prospective study aims to assess blood pressure changes, treatment adherence, quality of life, prescription patterns, and cardiovascular outcomes over up to three years. The study also compares Nebilet4 used alone versus in combination therapy and investigates the relationship between home and office blood pressure measurements. Participants include about 5,000 adults newly diagnosed with or having uncontrolled hypertension who have recently started Nebilet4 or been on it no more than two weeks. Patients are followed regularly for 12, 24, and 36 months, with blood pressure measured at each visit and home readings encouraged. The study collects data on medication dosing and frequency, adherence, and cardiovascular risk factors, while monitoring major adverse cardiac events such as heart attack, stroke, and cardiovascular death. During the study, participants complete questionnaires to assess quality of life and medication adherence every few months. Data are recorded through an electronic system ensuring consistency across sites. Researchers evaluate changes in systolic and diastolic blood pressure and the proportion achieving target blood pressure goals. Safety and any adverse events are documented, with follow-up visits extending up to three years to provide insights into the long-term management of hypertension with Nebilet4.